Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

24 results
  1. ... cancer include the following: Anthracyclines. - Doxorubicin. - Epirubicin. - Liposomal ... - Ixabepilone.[ 78 ] Combination regimens that have shown activity in metastatic breast cancer ...
  2. ... year follow-up Comparison 8. Doxorubicin/epirubicin + docetaxel/paclitaxel + CMF versus doxorubicin/epirubicin (± cyclophosphamide) + CMF Figure 119 Disease-free survival at 3. ...
  3. ... window Standard treatment Etoposide + cisplatin Etoposide + carboplatin Other regimens Cisplatin + irinotecan Ifosfamide + cisplatin + etoposide Cyclophosphamide + doxorubicin + etoposide Cyclophosphamide + doxorubicin + etoposide + vincristine Cyclophosphamide + etoposide + vincristine ...
  4. NLM Digital Collections - Treatment of primary breast cancer : a national clinical guideline 
    Publication: Edinburgh, Scotland : Scottish Intercollegiate Guidelines Network (SIGN), September 2013
    ... A, et al. Feasibility and tolerability of sequential doxorubicin/ paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor ...
  5. NLM Digital Collections - Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer : effectiveness and value : ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, September 28, 2017
    ... liposomal doxorubicin.7-9 For recurrence, several chemotherapy regimens (e.g., docetaxel, paclitaxel, gemcitabine, liposomal doxorubicin, topotecan and etoposide) may be used, with or ...
  6. NLM Digital Collections - Management of epithelial ovarian cancer : a national clinical guideline 
    Publication: Edinburgh, Scotland : Scottish Intercollegiate Guidelines Network (SIGN), 2013
    ... trial demonstrates equal effectiveness for carboplatin or CAP (cyclophosphamide, 1++ doxorubicin and cisplatin) compared with paclitaxel and carboplatin in ovarian cancer.133 ICON 3 ...
  7. ... Level of evidence: IV ] Capecitabine, cisplatin, cytosine arabinoside, cyclophosphamide, daunorubicin, docetaxel, doxorubicin, 5-fluorouracil, interferon, irinotecan, leucovorin, methotrexate, oxaliplatin, paclitaxel, topotecan, lapatinib, pertuzumab Radiation therapy (Refer to the ...
  8. ... among patients that had received NAC. The chemotherapy regimens evaluated in the AC trials were CMV, cisplatin/gemcitabine, cisplatin/methotrexate, and cisplatin/doxorubicin/cyclophosphamide. Table 6 Characteristics of studies on adjuvant and ...
  9. ... area (BSA) with or without additional agents, or doxorubicin 60 mg/m 2 of BSA with ... regimen included an NK-1 antagonist (fosaprepitant or aprepitant), ...
  10. ... e., cyclophosphamide and vincristine) cycles. Examples of other regimens that have been ... hydroxyurea, and vincristine. CHAMOMA: Methotrexate, folinic acid, ...
previous · 1 · 2 · 3 · next